Maryam Arjomand, MD
Obstetrics/Gynecology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 4 carriers
- Office
- 1
- Since medical school
- 32 years
- University of Chicago, Pritzker School of Medicine, 1994
Offices
1 location · UCSF Health Medical Foundation · 65 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Arjomand’s office at (510) 428-3000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$13,472
Medicare paid this office $13,472 for 92 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 63 | $6,192 | $75 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 49 | $2,326 | $47 |
| Return visit (30+ min) | 19 | $2,130 | $112 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $625 | $57 |
Who their Medicare patients are
92 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 0% · Health risk score 0.68. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 49% · Cancer 16% · Diabetes 14% · Chronic kidney disease 12% · Depression 12%.
The office billed $58,833, Medicare allowed $17,853 and paid $13,472; for 175 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 92 | 175 | 73 | 0.68 | $58,833 | $13,472 |
| 2023 | 80 | 142 | 74 | 0.76 | $41,657 | $11,186 |
| 2022 | 56 | 108 | 74 | 0.65 | $27,968 | $7,763 |
| 2021 | 65 | 109 | 74 | 0.66 | $22,330 | $7,922 |
| 2020 | 51 | 79 | 72 | 0.64 | $25,550 | $5,447 |
| 2019 | 79 | 151 | 74 | 0.75 | $46,775 | $10,943 |
| 2018 | 100 | 143 | 73 | 0.61 | $26,020 | $10,796 |
| 2017 | 123 | 197 | 74 | 0.70 | $17,233 | $11,382 |
| 2016 | 65 | 110 | 73 | 0.77 | $15,880 | $7,937 |
| 2015 | 55 | 91 | 73 | 0.74 | $11,137 | $6,735 |
| 2014 | 48 | 80 | 71 | 0.81 | $10,326 | $5,877 |
| 2013 | 41 | 82 | 70 | 0.63 | $8,038 | $5,384 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 53 | $5,629 | $83 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 40 | $1,875 | $47 |
| Return visit (30+ min) | 13 | $1,275 | $91 |
2022: 3 services
| Short return visit (20+ min) | 32 | $2,890 | $78 |
| Return visit (30+ min) | 18 | $2,163 | $90 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 33 | $1,532 | $46 |
2021: 3 services
| Return visit (30+ min) | 20 | $2,955 | $114 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $2,024 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 25 | $1,349 | $54 |
2020: 2 services
| Return visit (30+ min) | 27 | $2,628 | $73 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 19 | $898 | $47 |
2019: 4 services
| Return visit (30+ min) | 47 | $6,219 | $86 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 35 | $1,607 | $46 |
| Short return visit (20+ min) | 17 | $1,183 | $70 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 18 | $954 | $53 |
2018: 2 services
| Return visit (30+ min) | 83 | $8,629 | $79 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 17 | $741 | $44 |
2017: 3 services
| Return visit (30+ min) | 43 | $4,549 | $86 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 82 | $3,496 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 58 | $2,994 | $52 |
2016: 3 services
| Return visit (30+ min) | 27 | $4,280 | $91 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,273 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 22 | $1,183 | $54 |
2015: 3 services
| Return visit (30+ min) | 26 | $3,209 | $87 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | $975 | $42 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $624 | $52 |
2014: 3 services
| Return visit (30+ min) | 24 | $3,098 | $82 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | $688 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $576 | $52 |
2013: 3 services
| Return visit (30+ min) | 24 | $3,239 | $85 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 21 | $1,111 | $53 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $892 | $42 |
Drugs they prescribed that Part D paid
$23,259
Pharmacies billed $23,259 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 242) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
209 generic and 33 brand-name prescriptions · $23,259 in drug cost · 16 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 11 | $5,982 | $544 |
| Estradiol | 87 | $5,668 | $65 |
| Valacyclovir | 14 | $681 | $49 |
| Fluconazole | 31 | $125 | $4 |
Year by year
| 2024 | 242 | 70 | 0% (0) | 14% | $23,259 |
| 2023 | 180 | 57 | 0% (0) | None | $22,515 |
| 2022 | 120 | 45 | 0% (0) | None | $19,217 |
| 2021 | 114 | 39 | 0% (0) | 31% | $17,683 |
| 2020 | 130 | 46 | 0% (0) | 25% | $22,062 |
| 2019 | 114 | 45 | 0% (0) | 19% | $15,641 |
| 2018 | 115 | 47 | 0% (0) | 30% | $17,447 |
| 2017 | 111 | 51 | 0% (0) | 32% | $17,116 |
| 2016 | 93 | 30 | 0% (0) | 65% | $13,255 |
| 2015 | 109 | 36 | 0% (0) | 55% | $12,660 |
| 2014 | 92 | 31 | 0% (0) | 38% | $11,023 |
| 2013 | 63 | 26 | 0% (0) | 22% | $4,039 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Estring | 12 | $6,653 | $554 |
| Estradiol | 53 | $3,986 | $75 |
| Valacyclovir | 12 | $978 | $81 |
| Fluconazole | 15 | $51 | $3 |
2022: 5 drugs
| Premarin | 11 | $6,651 | $605 |
| Estring | 13 | $6,229 | $479 |
| Estradiol | 23 | $2,196 | $95 |
| Valacyclovir | 11 | $902 | $82 |
| Fluocinonide | 13 | $257 | $20 |
2021: 4 drugs
| Premarin | 14 | $7,747 | $553 |
| Estring | 13 | $5,960 | $458 |
| Estradiol | 20 | $1,371 | $69 |
| Nystatin | 11 | $138 | $13 |
2020: 3 drugs
| Premarin | 16 | $8,292 | $518 |
| Estradiol | 18 | $2,866 | $159 |
| Fluconazole | 11 | $52 | $5 |
2019: 2 drugs
| Estradiol | 23 | $3,383 | $147 |
| Nystatin | 13 | $145 | $11 |
2018: 5 drugs
| Premarin | 12 | $4,575 | $381 |
| Estring | 11 | $4,562 | $415 |
| Estradiol | 21 | $3,424 | $163 |
| Nystatin | 12 | $137 | $11 |
| Fluconazole | 12 | $77 | $6 |
2017: 1 drug
| Premarin | 12 | $4,734 | $395 |
2016: 3 drugs
| Premarin | 14 | $5,666 | $405 |
| Estring | 11 | $3,461 | $315 |
| Estradiol | 13 | $619 | $48 |
2015: 5 drugs
| Premarin | 15 | $5,022 | $335 |
| Estring | 15 | $3,836 | $256 |
| Nystatin-Triamcinolone | 12 | $1,099 | $92 |
| Estradiol | 14 | $625 | $45 |
| Fluconazole | 21 | $235 | $11 |
2014: 4 drugs
| Estring | 20 | $4,476 | $224 |
| Premarin | 12 | $4,373 | $364 |
| Estradiol | 14 | $515 | $37 |
| Fluconazole | 12 | $99 | $8 |
2013: 2 drugs
| Estradiol | 13 | $548 | $42 |
| Fluconazole | 18 | $226 | $13 |
Money from drug and device companies
$250 in 2025
| 2025 | 7 | 10 | None | $250 |
| 2024 | 2 | 4 | None | $122 |
| 2023 | 6 | 8 | None | $186 |
| 2022 | 4 | 7 | None | $149 |
| 2021 | 4 | 21 | None | $393 |
| 2020 | 6 | 8 | None | $152 |
| 2019 | 10 | 17 | None | $331 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $86 | 3 payments
|
| Biogen | Zurzuvae | $42 | 2 payments
|
| Mayne Pharma Commercial | None | $34 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $27 | 1 payment
|
| Minerva Surgical | None | $21 | 1 payment
|
| Hologic Sales and Service | Myosure Tissue Removal Device | $20 | 1 payment
|
See all 10 published payments
| Biogen | Meals · 2025-12-17 | Zurzuvae | $17 |
| Astellas Pharma US | Meals · 2025-08-06 | Veozah | $27 |
| Exact Sciences | Meals · 2025-07-22 | Cologuard Collection Kit | $27 |
| Minerva Surgical | Meals · 2025-06-18 | None | $21 |
| Mayne Pharma Commercial | Meals · 2025-05-21 | None | $34 |
| Biogen | Meals · 2025-05-07 | Zurzuvae | $25 |
| Astellas Pharma US | Meals · 2025-03-05 | Veozah | $28 |
| Astellas Pharma US | Meals · 2025-02-05 | Veozah | $31 |
| CooperSurgical | Meals · 2025-01-29 | Paragard T 380a | $19 |
| Hologic Sales and Service | Meals · 2025-01-09 | Myosure Tissue Removal Device | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $122
| Mayne Pharma Commercial | None | $102 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $19 | 1 payment
|
2023: $186
| Mayne Pharma Commercial | None | $66 | 3 payments
|
| Medicem | Dilapan-S | $30 | 1 payment
|
| AbbVie | Orilissa | $26 | 1 payment
|
| Hologic Sales and Service | Aptima | $25 | 1 payment
|
| CooperSurgical | Paragard T 380a | $19 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $19 | 1 payment
|
2022: $149
| Abbvie | Liletta | $82 | 4 payments
|
| Pfizer | Myfembree | $26 | 1 payment
|
| TherapeuticsMD | Annovera | $21 | 1 payment
|
| CooperSurgical | Paragard | $20 | 1 payment
|
2021: $393
| AbbVie | Lo Loestrin Fe | $241 | 14 payments
|
| TherapeuticsMD | Annovera | $90 | 4 payments
|
| Pfizer | Myfembree | $44 | 2 payments
|
| Daiichi Sankyo | Injectafer | $19 | 1 payment
|
2020: $152
| AbbVie | Lo Loestrin Fe | $43 | 2 payments
|
| Pfizer | Premarin | $40 | 2 payments
|
| Roche Diagnostics | Rs Harmony Test Related Products | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $19 | 1 payment
|
| CooperSurgical | Paragard | $16 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $14 | 1 payment
|
2019: $331
| AbbVie | Orilissa | $105 | 5 payments
|
| Roche Diagnostics | Rs Harmony Test Related Products | $63 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $34 | 2 payments
|
| CooperSurgical | Paragard | $28 | 1 payment
|
| Pfizer | Premarin | $20 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
| TherapeuticsMD | Imvexxy | $18 | 1 payment
|
| Allergan | Lo Loestrin Fe | $17 | 1 payment
|
| Vertical Pharmaceuticals | Divigel | $15 | 1 payment
|
| Avion Pharmaceuticals | Prenate Mini | $13 | 1 payment
|
Professional record
- NPI
- 1689763781
- Licence
- CA 00A617050, CA A061705
- Trained
- University of Chicago, Pritzker School of Medicine, 1994 · 32 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 136 N San Mateo Dr, #101, San Mateo, CA, 94401
- NPI first listed
- 2006-10-12
- NPI last updated
- 2015-04-24
This is when the NPI record was last certified, not a medical board exam.